NCT03897270 Photoacoustic Imaging of the Breast in Patients With Breast Cancer and Healthy Subjects
| NCT ID | NCT03897270 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Roswell Park Cancer Institute |
| Condition | Breast Carcinoma |
| Study Type | INTERVENTIONAL |
| Enrollment | 400 participants |
| Start Date | 2018-10-25 |
| Primary Completion | 2026-08-25 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 400 participants in total. It began in 2018-10-25 with a primary completion date of 2026-08-25.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This trial studies photoacoustic imaging of the breast in patients with breast cancer and healthy subjects. Dense breasts typically reduce the sensitivity of a mammography and also is associated with a higher risk of breast cancer. Photoacoustic tomography combines light and sound to provide more information about breast tissue.
Eligibility Criteria
Inclusion Criteria: * Women with clinically suspicious or confirmed breast cancer masses (that have not been surgically removed) and will/have already undergo/undergone breast magnetic resonance imaging (MRI). Exclusion Criteria: * Pregnant women (there are no known risks to these procedures, but any unforeseen risks are as yet undetermined, so pregnant women will be excluded by means of a verbal confirmation at time of screening). * Women who have had breast implants in the previous 6 months. * Women who have had lumpectomy * Adults unable to consent. * Individuals who are not yet adults (infants, children, teenagers). * Pregnant women. * Prisoners. * There is no direct benefit of the study to any subject either non-English or English speaker. To facilitate the consent process, we will exclude non-English speaking subjects.
Contact & Investigator
Ermelinda Bonaccio
PRINCIPAL INVESTIGATOR
Roswell Park Cancer Institute
Frequently Asked Questions
Who can join the NCT03897270 clinical trial?
This trial is open to female participants only, aged 18 Years or older, studying Breast Carcinoma. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT03897270 currently recruiting?
Yes, NCT03897270 is actively recruiting participants. Visit ClinicalTrials.gov or contact Roswell Park Cancer Institute to inquire about joining.
Where is the NCT03897270 trial being conducted?
This trial is being conducted at Buffalo, United States.
Who is sponsoring the NCT03897270 clinical trial?
NCT03897270 is sponsored by Roswell Park Cancer Institute. The principal investigator is Ermelinda Bonaccio at Roswell Park Cancer Institute. The trial plans to enroll 400 participants.